INTRODUCTION {#S1}
============

Hemophagocytic syndrome (HPS), also known as hemophagocytic lymphohistiocytosis (HLH), is characterized by the association of various clinical (fever and splenomegaly) and biological (cytopenias, hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia and hemophagocytosis) features, whose common pathophysiological basis is the reduction of cytotoxic activity and hyperproduction of inflammatory cytokines \[[@ref1]-[@ref3]\].

HPS has traditionally been categorized as primary (or genetic) or secondary (or reactive) \[[@ref1]-[@ref3]\]. Primary forms appear in childhood and are usually the result of genetic alterations affecting the cytotoxic T lymphocyte granules and natural killer (NK) cells. Secondary forms can develop at any age and are associated with a number of triggering factors, indicated below. HPS, especially its secondary forms, present data that overlap with macrophage activation syndrome \[[@ref4]\]

HPS is not a common process in adults (1 case per 800,000 people/year) with major geographical variations \[[@ref2]\]. The highest number of cases has been reported in Japan (\>500), followed by France (150-500), Spain, Italy and the United States (50-149) \[[@ref2]\]. The three main groups of triggering agents of HPS in adults are infections, malignancies and autoimmune processes, with major differences depending on the geographical region. Among infections, the most frequently involved agents are viruses (particularly the Epstein Barr virus \[EBV\] and cytomegalovirus \[CMV\]), followed by bacteria (mainly *Mycobacterium tuberculosis*), protozoa (above all *Leishmania* spp.) and fungi (typically *Histoplasma* spp.) \[[@ref2], [@ref5]-[@ref7]\]. The malignancies most frequently associated with HPS are lymphomas and related autoimmune disorders such as systemic lupus erythematosus (SLE) and adult Still's disease (ASD).

In the context of adult HPS, from the early years of HIV as an endemic infection, cases were reported of patients with HIV infection \[[@ref8]\] who presented certain distinctive characteristics from the standpoint of etiology, progression and therapy \[[@ref9]-[@ref11]\]. Although there are some case series of patients and individual case ([tables 1](#T1){ref-type="table"}-[2](#T2){ref-type="table"}), the information is scarce, so that it is worth reviewing the experience in our center and comparing the characteristics in our series (clinical and microbiological features, and outcome) with those published by other authors.

###### 

Case series of hemophagocytic syndrome in HIV-infected patients. General characteristics.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                             Pellegrin \[[@ref18]\]   Bourquelot \[[@ref19]\]   Tiab \[[@ref10]\]   Sailler \[[@ref20]\]   Grateau \[[@ref21]\]   Fardet \[[@ref22]\]   Stebbing \[[@ref23]\]   Fardet \[[@ref24]\]a   Townsend \[[@ref25]\]        Lerolle \[[@ref26]\]b   Telles \[[@ref27]\]
  ---------------------------------------------------------- ------------------------ ------------------------- ------------------- ---------------------- ---------------------- --------------------- ----------------------- ---------------------- ---------------------------- ----------------------- ---------------------
  Nº patients                                                2                        5                         5                   16                     9                      5                     4                       43                     9                            19                      21

  Age (years). Mean                                          31                       33                        35                  \-                     46                     \-                    40                      \-                     42                           \-                      36

  Sex (M/F). Number                                          2/0                      4/1                       5/0                 \-                     7/2                    1/4                   4/0                     \-                     7/2                          \-                      19/2

  Origin. %                                                  \-                       \-                        \-                  \-                     \-                     • Africa: 60%\        • Africa: 50%\          \-                     • North America: 78%\        \-                      \-
                                                                                                                                                                                  • Caribbean:20%\      • Europe: 50%                                  • Central America:11%\                               
                                                                                                                                                                                  • Europe:20%                                                         • Unknown: 11%                                       

  Fever                                                      2 (100%)                 5 (100%)                  \-                  15 (94%)               7 (78%)                5 (100%)              4 (100%)                43 (100%)              7 (78%)                      19 (100%)               21 (100%)

  Splenomegaly                                               1 (50%)                  4 (80%)d                  \-                  \-                     3 (33%)                5 (100%)              3 (75%)                 36 (84%)               9 (100%)                     \-                      19 (90%)

  Hemoglobin \< 9 g/dL                                       1 (50%)                  5 (100%)                  \-                  \-                     6 (67%)                5 (100%)              4 (100%)                \-                     9 (100%)                     \-                      \-

  Neutrophils \< 1000/mL                                     0                        3 (60%)                   \-                  \-                     2 (22%)                2 (40%)               \-                      \-                     \-                           \-                      \-

  Platelets \< 100000/mL                                     1 (50%)                  5 (100%)                  \-                  \-                     2 (22%)                3 (60%)               2 (50%)                 \-                     9 (100%)                     \-                      \-

  Triglyceridemia \> 265 mg/dL                               1 (50%)                  3 (60%)                   \-                  \-                     0                      5 (100%)              3 (75%)                 \-                     \-                           \-                      

  Fibrinogen levels\< 1,5 g/L                                0                        2 (40%)                   \-                  \-                     \-                     3 (60%)               0                       \-                     \-                           \-                      

  Hemophagocytosis                                           2 (100%)                 5 (100%)                  5 (100%)            \-                     9 (100%)               5 (100%               4 (100%)                \-                     7 (78%)                      \-                      

  Elevated ferritin                                          1 (50%)                  2 (40%)                   \-                  \-                     1 (11%)                5 (100%)              4 (100%)                \-                     8 (89%)                      \-                      21 (100%)

  Respiratory symptoms                                       1 (50%)                  4 (80%)                   \-                  \-                     \-                     5 (100%)              \-                      \-                     \-                           \-                      \-

  Neurological symptoms                                      \-                       2 (40%)                   \-                  \-                     4 (44%)                2 (40%)               \-                      \-                     \-                           \-                      \-

  Hepatomegaly                                               2 (100%)                 4 (80%)                   \-                  \-                     8 (89%)                3 (60%)               4 (100%)                \-                     \-                           \-                      \-

  Lymphadenopathy                                            1 (50%)                  4 (80%)                   \-                  \-                     4 (44%)                5 (100%)              4 (100%)                \-                     \-                           \-                      8 (38%)

  Disseminated intravascular coagulation                     \-                       2 (40%)                   \-                  \-                     4 (44%)                \-                    \-                      \-                     \-                           \-                      \-

  Hypertransaminasemia                                       0                        3 (60%)                   \-                  \-                     7 (78%)                \-                    \-                      \-                     \-                           \-                      \-

  Risk practices for HIV infection (%)                       MSM:100%                 MSM: 80%\                 \-                  \-                     MSM: 56%\              MSM: 20%\             \-                      \-                     \-                           \-                      \-
                                                                                      IDU: 20%                                                             HTX : 33%\             HTX: 80%                                                                                                                  
                                                                                                                                                           IDU:11%                                                                                                                                          

  Duration of HIV infection in months (mean and interval)    -c                       \-                        65 (36-120)         \-                     \-                     \-                    \-                      48 (0-240)             \-                           \-                      96

  Plasma HIV RNA at diagnosis of HPS (copies/mL). Interval   \-                       \-                        \-                  \-                     \-                     50-25.000             50-500.000              20-2.800.000           0-10.000.000                 50316.000               \-

  ART admission                                              1 (50%)                  \-                        \-                  \-                     \-                     \-                    2 (50%)                 25 (58%)               4 (44%)                      \-                      \-

  CD4/μL (mean and interval)                                 78e                      305 (11-818)              36 (0-70)           30 (6-475)             16 (0-64)              200 (165-234)         247 (71-492)            104 (2-387)            13 (1-50)                    21 (16-101)             82

  CD8/μL (mean and interval)                                 \-                       1053 (200-3500)           \-                  \-                     \-                     \-                    \-                      391 (33-2618)          \-                           \-                      \-

  Specific treatment for HPS                                 \-                       Corticosteroids\          \-                  \-                     \-                     Etoposide\            Etoposide\              \-                     Corticosteroids\             \-                      \-
                                                                                      Splenectomy                                                                                 Splenectomy           Splenectomy Rituximab                          Intravenous immunoglobulin                           

  Mortality in the first 30 days                             1 (50%)                  4 (80%)                   3 (60%)             8 (50%)                9 (100%)               2 (40%)               0                       \-                     5 (56%)                      \-                      \-

  Survival (days) in patients who died (mean and interval)   43                       60-150                    30 (10-50)          \-                     198 (60-360)           \-                    \-                      \-                     54 (9-221)                   \-                      \-
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The data has been expressed in number of patients (n) and frequencies (%)

Only the data referring to patients with confirmed HPS diagnosis are provided (n: 43 patients). ^b^Only the data referring to patients with HPS and HIV infection are provided (no: 19 patients). ^c^Primary infection ^d^One patient was splenectomized. ^e^Value obtained from a single patient. MSM: Men who have sex with men; HTX: Heterosexual contact; IDU: Injecting Drug Users.

###### 

Characteristics of single cases of hemophagocytic syndrome in HIV-infected patients.

  Group                 Subgroup                                          Author                                         References                                              Year   HIV-infected admission   Age            Sex             Origin        CD4/L           ART               Treatment \*   Mortality
  --------------------- ------------------------------------------------- ---------------------------------------------- ------------------------------------------------------- ------ ------------------------ -------------- --------------- ------------- --------------- ----------------- -------------- -----------
  Virus                 HIV                                               Gotoh                                          Br J Haematol. 2001;112:1090                            2001   No                       35             Male            \-            100             Yes               No             No
  Alliot                Hematology. 2001;5:4758                           2001                                           No                                                      51     Male                     North Africa   42              Yes           No              Yes                              
  Castilleti            Clin Infect Dis. 2004;38:17923                    2004                                           Yes (acute HIV infection)                               27     Male                     Italy          138             No            No              No                               
  Chen                  Int J Hematol. 2003;78:4502                       2004                                           Yes                                                     18     Male                                    590             No            IVIG            No                               
  Adachi                Intern Med. 2013;52: 62932                        2013                                           Yes (acute HIV infection)                               48     Male                     Japan          98              No            No              No                               
  Ferraz                BMC Infect Dis. 2016;16:619                       2016                                           Yes (acute HIV infection)                               27     Female                                  13              No            Co              No                               
  Usman                 Int J STD AIDS. 2016;27:4113                      2016                                           Yes                                                     24     Male                                    331             No            Co              No                               
  Manji                 BMC Infect Dis. 2017;17:633                       2017                                           Yes (acute HIV infection)                                      Male                                    137             No            No              No                               
  Fitzgerald            Case Rep Crit Care. 2017;2017:8630609             2017                                           No                                                      30     Female                   Caucasian      4               No            Co              No                               
  EBV                   Albretch                                          Arch Pathol Lab Med. 1997;121:8538             1997                                                    No     26                       Male                           70            No              Co + S+ IVIG      Yes            
  Wong                  Arch Intern Med. 2007;167:19013                   2007                                           No                                                      46     Male                     China          204             Yes           Et +IVIG        Yes                              
  Flew                  Int J STD AIDS. 2010;21:6013                      2010                                           No                                                      46     Male                     Africa         314             Yes           Co              No                               
  Thoden                J Infect. 2012;64:1102                            2012                                           No                                                      70     Male                                    284             Yes           Co + Et + Ri    Yes                              
  Khagi                 Clin Adv Hematol Oncol. 2012;10(4):260-2          2012                                           No                                                      58     Male                                    40              Yes           Co + Ri         Yes                              
  Sculier               J Int AIDS Soc. 2014;17(4 Suppl 3):19650          2014                                           No                                                      29     Male                                    438             Yes           Co + Et + Ri                                     
  Koizumi               J Clin Immunol. 2018;38:478483                    2018                                           No                                                      53     Male                     Japan          7               Yes           No              Yes                              
  Shaikh                BMJ Case Rep. 2018;2018. pii: bcr2018224424       2018                                           Yes                                                     33     Male                                    42              No            Co              No                               
  HHV-8                 Yates                                             AIDS Read. 2007;17:5968                        2007                                                    No     45                       Male                           64            Yes             Cf + Co + S+ Ri   Yes            
  Seliem                Am J Surg Pathol. 2007;31:143945                  2007                                           No                                                      45     Male                                    64              Yes           Cf + S + Ri     Yes                              
  Ramon                 Acta Clin Belg. 2010;65:2768                      2010                                           No                                                      40     Male                     Congo          90              Yes           No              No                               
  Shah                  Clin Lymphoma Myeloma Leuk. 2014;14:e15760        2014                                           No                                                      33     Male                                    60              No            Co + Ri         No                               
  Zorzou                Hematol Rep. 2016;8:6581                          2016                                           No                                                      40     Male                                    39              No            Co + IVIG       No                               
  Bangaru               BMJ Case Rep. 2017;2017. pii: bcr2017222382       2017                                           No                                                      45     Male                                    17              Yes           Co              Yes                              
  CMV                   Ohkuma                                            BMJ Case Rep. 2013;2013. pii: bcr2013200983    2013                                                    No     29                       Male                           156           No              No                No             
  Parvovirus            Alliot                                            Eur J Clin Microbiol Infect Dis. 2001;20:435   2001                                                    No     34                       Male           South America   34            Yes             No                Yes            
  Fungi                 *Histoplasma*spp.                                 Guiot                                          Diagn Microbiol Infect Dis. 2007;57:42933               2007   Yes                      43             Male            Puerto Rico   66              No                No             No
  Sánchez               AIDS Read. 2007;17:4969                           2007                                           Yes                                                     61     Male                     Mexico         4               No            No              No                               
  De Lavaissière        J Infect. 2009;58:2457                            2009                                           No                                                      33     Male                     Guyana         13              No            IVIG            No                               
  Subedee               J Int Assoc Provid AIDS Care. 2015;14:3917        2015                                           No                                                      42     Female                   USA            40              No            No              No                               
  Castelli              Open Forum Infect Dis. 2015;2:ofv140              2015                                           No                                                      32     Male                     Mexico         3               No            Co + Et         No                               
  Nieto                 Biomedica. 2016;36:914                            2016                                           No                                                      33     Male                     \-             16              No            No              No                               
  Gómez                 Myco-pathologia. 2017;182:767770                  2017                                           Yes                                                     23     Male                     Venezuela      7               Yes           Co + IVIG       No                               
  Ocon                  BMJ Case Rep. 2017;2017. pii: bcr2017221264       2017                                           No                                                      49     Male                     Guyana         7               No            A + Co + IVIG   No                               
  Loganantharaj         Int J STD AIDS.2018;29: 925928                    2018                                           No                                                      46     Male                     D. Republic    54              No            No              No                               
  Zanotti               Mediterr J Hematol Infect Dis. 2018;10:e2018040   2018                                           Yes                                                     19     Female                   Ivory Coast    19              No            Co              No                               
  Tsuboi                Am J Trop Med Hyg. 2019;100:365367                2019                                           Yes                                                     56     Female                   Venezuela      13              No            No              No                               
  *Penicillium*spp.     Pei                                               Am J Trop Med Hyg. 2008;78:113                 2008                                                    Yes    34                       Male                           119           No              Co + IVIG         No             
  *Candida*spp.         Bathia                                            Clin Infect Dis. 2003;37:e1616                 2003                                                    No     38                       Female                         65            Yes             Co + IVIG         Yes            
  *Aspergillus*spp.     Delcroix                                          Rev Med Liege. 2006;61:7138                    2006                                                    Yes    31                       Female         Yugoslavia                    No              Co + IVIG         Yes            
  Protozoan parasites   *Leishmania*spp.                                  Patel                                          J Int Assoc Physicians AIDS Care (Chic). 2009;8:21720   2009   No                       35             Male                          234             No                No             No
  *Toxoplasma*spp.      Guillaume                                         Eur J Intern Med. 2006;17:5034                 2006                                                    No     33                       Male           Rwanda          6             Yes             Co + IVIG         Yes            
  Bacteria              *Bartonella*spp.                                  Le Joncour                                     Clin Infect Dis. 2016;62:8046                           2016   Yes                      69             Male            Mali          20              No                Et             No
  *Ehrlichia*spp.       Naqash                                            Ann Hematol. 2017;96: 17551758                 2017                                                    No     66                       Female         Africa          0             Yes             Co + Et           Yes            
  Mycobacteria          *M. xenopi*                                       Nuño                                           Enferm Infecc Microbiol Clin. 2000;18:967               2000   No                       25             Female          \-            9               No                Co             Yes

A: Anakinra; Cf: Cyclophosphamide; Co: Corticosteroids; S: Splenectomy; Et: Etoposide; IVIG: Intravenous immunoglobulin; Ri: Rituximab

METHODS {#S2}
=======

**Study design**. A retrospective descriptive observational analysis of a case series was performed.

**Scope of study**. To evaluate epidemiological, etiological, clinical and evolutionary characteristics of patients diagnosed with hemophagocytic syndrome and HIV infection.

**Inclusion and exclusion criteria**. Included were all adult patients (\>14 years) with a diagnosis at discharge of HPS and HIV infection who were treated in the Infectious Diseases and Tropical Medicine Unit (IDTMU) of the Hospital Universitario Insular in Las Palmas, Gran Canaria. between June 1, 1998 and December 31, 2018. Henter's criteria were used for the HPS diagnosis ([table 3](#T3){ref-type="table"}) \[[@ref12]\]. Mutations in genes compatible with a molecular diagnosis of HLH, increased levels of soluble CD25, and NK cell activity were not analyzed because of difficulties of access in our environment. Data were obtained after a detailed, comprehensive review of the clinical history of each patient. Excluded were patients who did not present HIV infection.

###### 

Diagnostic criteria of hemophagocytic syndrome [\*](#TF3-1){ref-type="table-fn"}

  -----------------------------------------------------------------------------------------
  1\. Fever \> 38.5º C

  2\. Splenomegaly

  3\. Peripheral blood cytopenia, along with at least two of the following:\
  Hemoglobin \< 9g/dL\
  Neutrophils \< 1,000/L\
  Platelets \< 100,000/L

  4\. Hypertriglyceridemia \> 265 mg/dl, or fibrinogen levels \< 1.5 g/L

  5\. Hemophagocytosis (bone marrow, lymph nodes or spleen) without evidenceof malignancy

  6\. Low or absent NK cell activity

  7\. Ferritin levels \> 500 ng/mL

  8\. Elevated soluble CD25 levels (\> 2,400 U/mL)
  -----------------------------------------------------------------------------------------

If 5 of the 8 criteria listed are fulfilled.

**Methodology**. For each patient, the following demographic data were recorded: age at the time of diagnosis, sex, geographic origin. Other essential data about HIV infection were also included, such as year of diagnosis, risk practices for acquiring HIV infection, medical history of interest, opportunistic infections prior to current HPS admission and co-infections. Other measures evaluated were: type of HIV, subtype and antiretroviral drug resistance, nadir CD4/μL count, viral load at the time of HIV infection diagnosis, antiretroviral therapy (ART) at admission, time in follow-up and compliance with ART. The time interval between diagnosis of HIV infection and the presence of HPS was also noted, indicating whether the HIV infection diagnosis was recent. For confirmation of the HPS diagnosis, the following variables were recorded: fever, presence of splenomegaly, cytopenias, triglycerides in blood, fibrinogen levels, presence of hyperferritinemia, bone marrow aspiration performed and observation of hemophagocytosis. Other data recorded included: time from onset of symptoms until HPS diagnosis, neurological symptoms, hepatomegaly, lymphadenopathies, basic analytic data (procalcitonin, erythrocyte sedimentation rate, C-reactive protein, total proteins in blood plasma, transaminases, LDH activity, urea, creatinine, natremia and Quick index). With respect to HIV, the following lymphocyte subpopulation values (total and percentage) were analyzed: B lymphocytes (CD19), T lymphocytes (CD3), CD4 and CD8 lymphocytes, CD4/CD8 ratio and NK cells (CD3-/CD56+). Finally, the etiology of HPS was evaluated, the specific therapy used to treat HPS, as well as the etiological therapy, the need for ICU admission, total days spent in hospital, and prognosis (survival after diagnosis of HPS, survival or mortality in the first 30 days).

**Limitations**. The present study has certain limitations. First, it is likely that some cases of HPS were not suspected or were mistaken for sepsis or immune reconstitution inflammatory syndrome. Second, various patients with a probable diagnosis (only 4 of Henter's criteria) were not included in the interests of methodological rigor (one was triggered by *Histoplasma capsulatum)*. Third, the retrospective study design and the fact that it spanned a period of 20 years made it difficult to obtain some information, either to recover records or because of the limitation of additional tests available at any one time. Finally, therapeutic strategies were not clear and unambiguous, so that patient progress and prognosis may have been influenced by this heterogeneity.

**Statistical analysis**. Statistical analysis of the data obtained in the course of the present study was carried out using the SPSS statistical package, V22. Descriptive data were expressed as percentages (qualitative) or using measures of central tendency and dispersion (arithmetic mean and standard deviation, for normal distributions, or median and interquartile range for non-normal distributions).

RESULTS {#S3}
=======

**Clinical cohort**. Of the 3,066 HIV-infected cases followed between June 1, 1998 and December 31, 2018, 15 fulfilled the criteria for HPS. The distribution of cases according to year was: 1 patient in each of the following years: 2003, 2006, 2010, 2012, 2014, 2015 and 2018; 2 patients in 2011 and 2016, and 4 patients in 2013.

**Epidemiological characteristics**. 11 of the 15 patients were male and the mean age was 42 years (range 20-67). Ten patients were European (7 from Spain) and the rest came from sub-Saharan Africa (4) and the Caribbean (1).

**Clinical characteristics and laboratory findings**. [Table 4](#T4){ref-type="table"} shows the diagnostic criteria for HPS present in the study group and other clinical and biological data of patients included in this series. [Table 5](#T5){ref-type="table"} indicates characteristics related to HIV infection in this group of patients. The study of blood lymphocyte subpopulations is shown in [table 6](#T6){ref-type="table"}.

###### 

Clinical characteristics and laboratory findings of hemophagocytic syndrome

  -----------------------------------------------------------------------
  DIAGNOSTIC CRITERIA OF HPS                    n (%)       Range
  --------------------------------------------- ----------- -------------
  Fever                                         15 (100)    

  Splenomegaly                                  11 (73.3)   

  Cytopenias\                                   15 (100)    
  (along with at least two of the following):               

  Hemoglobin \<9 g/dL                           14 (93.3)   5.6-8.7

  Neutrophils \<1,000/mL                        8 (53.3)    0-600

  Platelets \<100,000/mL                        15 (100)    2,000-9,200

  Triglycerides \>265 mg/dL                     11 (73.3)   283-900

  Hemophagocytosis                              11 (73.3)   

  Elevated ferritin levels \> 500 ng/mL         15 (100)    550-10,105

  OTHER CHARACTERISTICS                         n (%)       Range

  Neurological symptoms                         5 (33.3)    

  Hepatomegaly                                  6 (40)      

  Lymphadenopathy                               7 (46.6)    

  Procalcitonin \> 0.5 ng/mL                    7 (46.6)    1.5-75.7

  Erythrocyte sedimentation rate \>12 mm        11 (73.3)   20-132

  C-reactive protein \>0.5 mg/dL                14 (93.3)   0.6-30.6

  Total protein \< 6.4 g/dL                     11 (73.3)   3.6-5.8

  Aspartate aminotransferase \>37 U/L           8 (53.3)    45-143

  Alanine aminotransferase\>45 U/L              5 (33.3)    47-195

  Gamma-glutamyl transpeptidase \> 55 U/L       10 (66.6)   75-1,112

  Lactate dehydrogenase \>248 U/L               10 (66.6)   256-5,984

  Urea \>43 mg/dL                               10 (66.6)   60-512

  Creatinine \> 1.17 mg/dL                      6 (40)      1.2-4.8

  Serum sodium \< 135 mM/L                      9 (60)      127-134

  Indice Quick \<70%                            8 (53.3)    44-66
  -----------------------------------------------------------------------

The data has been expressed in number of patients (n) and frequencies (%)

###### 

Clinical characteristics and laboratory findings of HIV infection.

  ------------------------------------------------------------------- ---------------------
  Risk practices for HIV infection                                    MSM: 7 (46.6)
  HTX: 7 (46.6)                                                       
  IDU: 1 (6.6)                                                        
  Coinfection                                                         No: 11 (73.3)
  Yes: 3 (20) (Chronic hepatitis B)                                   
  Unknown: 1 (6.6)                                                    
  Type of HIV                                                         Type 1: 11 (73.3)
  Type 2: 1 (6.6)                                                     
  Unknown: 3 (20)                                                     
  Subtype of HIV-1                                                    B: 8 (72.7)
  Circulating Recombinant Forms: 3 (27)                               
  Genotypic resistance test                                           Yes: 11 (73.3)
  Unknown: 4 (26.6)                                                   
  Nadir CD4/ μL (mean and standard deviation)                         303 (409)
  Plasma HIV RNA (copies/mL) (median and range)                       411,000 (9,989,200)
  HIV recent diagnosis                                                7 (46.6)\*
  Duration of HIV infection in months (mean and standard deviation)   27 (38)
  Plasma HIV RNA at diagnosis of HPS \<50 copies                      3 (20)
  Plasma HIV RNA at diagnosis of HPS (copies/mL) (median and range)   20,670 (7,299,999)
  ART at admission                                                    9 (60)
  ART schedule                                                        
  NRTIs                                                               9 (100)
  NNRTIs                                                              5 (55)
  PIs                                                                 4 (44)
  INSTIs                                                              2 (22)
  Duration of ART in days (mean and standard deviation)               84 (90)
  ------------------------------------------------------------------- ---------------------

The data has been expressed in number of patients (n) and frequencies (%) \*One patient had acute HIV infection.

N and %: Number of patients (n) and frequencies (%), MSM: Men who have sex with men; HTX: Heterosexual contact; IDU: Injecting Drug Users; NRTIs: Nucleoside reverse transcriptase inhibitors; NNRTIs: Non-nucleoside reverse transcriptase inhibitors; PIs: Protease inhibitors; INSTIs: Integrase inhibitors.

###### 

Blood lymphoid subsets\*

  ---------------- ---------------
  CD3/ μL          648 (50-1656)
  CD4/μL           1332 (3-996)
  CD4/ μL \<500    14 (93%)
  CD4/ μL \<200    12 (80%)
  CD8/μL           475 (44-1056)
  CD8/μL low       3 (20%)
  CD8/μL normal    6 (40%)
  CD8/μL high      3 (20%)
  CD4/CD8 ratio    0.27 (0-1.7)
  CD19/μL          146 (17-530)
  CD19/μL low      6 (40%)
  CD19/μL normal   5 (33%)
  CD19/μL high     1 (7%)
  CD3-/CD56 +/μL   62 (5-219)
  ---------------- ---------------

Subset data are expressed as mean and range.

**Etiological triggers**. In 8 patients, the trigger was HHV type 8 (isolated in 5 cases and associated with *P. jirovecii* in two patients and Epstein Barr virus in another). The rest of the cases corresponded to other viruses (Cytomegalovirus in 2 cases), mycobacteria (*M. tuberculosis* and *M. chelonae*), fungi (*Blastocystis dermatitidis*) and neoplasms (Hodgkin's disease). No other triggering agent was found in one patient.

**Treatment and follow-up**. The main aspects of patient management and patient outcomes are shown in ([tables 7](#T7){ref-type="table"}-[8](#T8){ref-type="table"}).

###### 

Treatment of hemophagocytic syndrome

  ---------------------------------------------- ----------
  Specific treatment for HPS                     15 (100)
  Corticosteroids                                6 (40)
  Corticosteroids + etoposide                    3 (20)
  Corticosteroids + intravenous immunoglobulin   2 (13.3)
  Corticosteroids + cyclosporine                 1 (6.6)
  Corticosteroids + liposomal adriamycin         1 (6.6)
  Corticosteroids + doxorubicin                  1 (6.6)
  Corticosteroids + cyclophosphamide             1 (6.6)
  ---------------------------------------------- ----------

The data has been expressed in number of patients (n) and frequencies (%)

###### 

Follow-up of hemophagocytic syndrome

  --------------------------------------------------------------------------------------------- -------------
  Duration of symptoms until confirmation of HPS, in days (mean and standard deviation)         32 (37.7)
  Transfer to intensive care unit \*                                                            7 (46.6)
  Length of hospital stay in days (mean and standard deviation)                                 34 (21.3)
  Survival after diagnosis of HPS in patients who died, in days (mean and standard deviation)   14.7 (10.4)
  Mortality in the first 30 days after diagnosis of HPS \*                                      11 (73.3)
  --------------------------------------------------------------------------------------------- -------------

The data has been expressed in number of patients (n) and frequencies (%)

DISCUSSION {#S4}
==========

Thanks to the efficacy of ART, a large number of patients with HIV infection currently remain asymptomatic during the course of the illness. In another group of patients, principally those with late diagnosis (starting CD4 count of \<350 cells/μL), infections develop (both opportunistic and not) that can be controlled with specific treatment. There is however another group of patients with HIV infection whose clinical manifestations are serious or very serious. The three main situations that lead to this picture are septic hemophagocytic syndrome \[[@ref8]-[@ref11]\], shock \[[@ref13]\] and immune reconstitution inflammatory syndrome \[[@ref14]\]. Nevertheless, the boundaries between them are not always clear cut, and situations may arise in which various of the diagnostic criteria coexist \[[@ref15]-[@ref17]\].

The characteristics of the patients in our series present certain similarities to and also various differences from those described in the literature, both in case series and isolated communications.

The incidence of HPS in our series of patients was 5/1,000 HIV-infected persons. There are no equivalent data in the lit-erature to make comparisons. The number of patients included in the different case series ranges between 2 and 43, with the majority of studies being single-center \[[@ref18]-[@ref27]\].

In our series, the ratio of males to females was 2.75:1 and the mean age was 42 years, similar to those indicated in the literature, although males were less predominant (4:1 overall). The patients studied were of very diverse origins, with a third being of non-European origin (sub-Saharan Africa and the Caribbean), which is of importance primarily for type of triggering factor.

In our study, all the patients presented fever, cytopenias and elevated ferritin levels. Fever is one of the characteristic manifestations of HPS and appears in 100% of patients in most of the series \[[@ref18], [@ref19], [@ref22]-[@ref24], [@ref26], [@ref27]\], and at least 75% of patients in others \[[@ref20], [@ref21], [@ref25]\]. The presence of cytopenia (especially anemia and thrombocytopenia) is usual in the published series, although the percentage of patients in which it is reported ranges from 22 to 100% \[[@ref18], [@ref19], [@ref21]-[@ref23], [@ref25]\]. Elevated serum ferritin is a distinctive marker with a negative prognostic value in HPS \[[@ref27]\]. The results in different series are variable, principally because this measure was not evaluated in all the patients included. Whilst it is reasonable to assume, given its name (hemophagocytic syndrome), that it is present in all patients by demonstrating its presence in bone marrow, lymph nodes, liver and spleen, it is possible to diagnose HPS without histologic evidence of hemophagocytosis. In our series, 73% of patients presented splenomegaly, and in other series, it varied from 0 to 100% \[[@ref18], [@ref19], [@ref21]-[@ref25], [@ref27]\]. Three quarters of patients included in this study presented hypertriglyceridemia, which is similar to figures indicated in the literature \[[@ref18], [@ref19], [@ref22], [@ref23]\]. Measurements of fibrinogen, NK cell activity and soluble CD25 receptor levels are unusual in the bibliography.

In our series, the most frequently encountered clinical manifestations of HPS not included in its definition were neurological (33% of patients). Respiratory manifestations were not observed. In the literature, the frequency of neurological alterations is similar to that found in our study \[[@ref19], [@ref21], [@ref22]\], whereas respiratory affectation varies considerably (0-100%) \[[@ref18], [@ref19], [@ref22]\]. The presence of hepatomegaly, lymphadenopathies and liver function test alterations was observed in 4060% of patients studied, with similar values to those found in other series \[[@ref18], [@ref19], [@ref21]-[@ref23], [@ref27]\].

There was no single pattern of HIV infection in our patients. Consequently, the risk practices for acquiring HIV infection were different and probably reflected local epidemiological patterns \[[@ref18], [@ref19], [@ref22], [@ref23]\]. In general, severe immunosuppression (\<200 CD4/ μL) and a detectable viral load at the time of diagnosis were common, although in our series and also in the literature, some cases of HPS presented higher CD4 values and undetectable viral loads \[[@ref18]-[@ref27]\]. Approximately half the patients were not in receipt of antiretroviral treatment, although the remainder were being treated \[[@ref18], [@ref23]-[@ref25]\]. Th *e* interval between diagnosis of HIV infection and HPS varied considerably (0-240 days), which has also been described in the literature \[[@ref10], [@ref24], [@ref27]\]. Finally, it should be mentioned that one of the patients in our series presented HPS at the same time as primary HIV infection. This has been described in the literature and is generally associated with a better prognosis.

The analysis of factors that trigger HPS in patients with HIV infection is complex for a number of reasons: *i)* The diagnostic methodology varies depending on the date and the scope of the study, and consequently, in certain patients, the precipitating factor appears as undetermined; *ii)* In quite a few cases, categorizing the trigger as malignancy or infection is arbitrary. This is particularly common in EBV infections and Hodgkin's disease, and also in those due to HHV-8 and a number of associated malignancies (Kaposi's sarcoma, Castleman's disease); *iii)* Some causative agents (e.g. *Histoplasma* spp.) have a restricted geographic distribution, and *iv)* Frequently, two or more triggering agents are associated together in the same patient. Bearing these considerations in mind, several conclusions can be drawn from the analysis of triggering factors in patients included in our study: *i)* In three patients, two or more triggering factors were identified; *ii)* The most common *triggers* were infections, particularly, viral infections;*iii)* Apart from HIV itself, the most frequently involved virus in our series was *HHV-8*; *iv)* Among fungi, three triggering agents were found in our series: *Pneumocystis jirovecii, Candida albicans* and *B. dermatitidis*. In this context, it should be pointed out that we have not found any references to the participation of *B. dermatitidis* in triggering HPS; v) The two mycobacteria related to HPS in our series were *M. tuberculosis* and *M. chelonae*. We also point out that we have not found bibliography on the role of *M. chelonae* as a trigger of HPS.

The three main pillars of treatment of HPS are \[[@ref2], [@ref12]\]: etiological, pathogenic and symptomatic. In entities where there is a causal treatment, the elimination or control of the triggering agent helps reduce the inflammatory stimulus. In this context, the limited therapeutic options in EBV and HHV-8 infections determine a worse prognosis. Pathogenic (sometimes called specific) treatment includes measures aimed at controlling the inflammatory response. The so-called HLH-2004 protocol (dexamethasone, cyclosporine, etoposide) \[[@ref28]\] constitutes the accepted basis for treatment, although it is rare in practice, both in our series and in other published cases. Other measures employed, alone or in combination, included intravenous immunoglobulins, cyclophosphamide or rituximab. Splenectomy may have a role in cases of splenomegaly and/ or hypersplenism. In the presence of neurological symptoms, a neuroimaging scan and lumbar puncture are mandatory to identify the mechanism and, if there is affectation, prednisone and intrathecal methotrexate should be used. In addition, the beneficial role of "personalized therapy" should be mentioned, as well as the use of anakinra/tocilizumab for the treatment of HPS, although more studies are necessary \[[@ref4]\]. Finally, symptomatic or support treatment includes platelet transfusion, fresh frozen plasma, transfusion of red blood cells and granulocyte colony-stimulating factors (G-CSF) for cases of severe neutropenia (although in isolated cases, administration of GSFs has been associated with exacerbation of HPS).

Thirty-day mortality due to HPS in our series was 75%, a figure intermediate between 40 and 100% described in other series \[[@ref10], [@ref18]-[@ref22], [@ref25]\]. Although it is impossible to be certain, various factors can influence this outcome (such as triggering factor, control of HIV infection, basal state of the immune system), which means that hospital stays are longer, as well as admission to ICU.

In conclusion, HPS is not so infrequent among HIV patients and should be suspected in the presence of fever and cytopenias. There is no characteristic onset profile and it can appear at different times, with different degrees of immune-suppression, in the presence or absence of ART. HIV infection and HHV-8 are the main triggers and other causative agents such as *B. dermatitidis* and *M. chelonae* also play a role in this context. Treatment is ill-defined, and is one of the reasons for poor patient outcomes.
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